Aim: Dienogest, a novel progestational 19-norsteroid, has been shown to have a therapeutic effect on endometriosis with its major side-effect being irregular genital bleeding. This study aimed to investigate the mechanism responsible for the bleeding seen during dienogest therapy.
Methods: For this multicenter, single-dose, open-label study, dienogest at a daily oral dose of 2 mg was administered for 16 weeks to nine patients with endometriosis showing regular menstrual cycles. Weekly determinations of serum endocrine hormone levels during the course of the treatment period and histological endometrial biopsies at the onset of genital bleeding were undertaken.
Results: All cases showed genital bleeding irregularly during the treatment period. Endometrial histological findings at the time of presentation of the bleeding revealed a secretory, inert or atrophic appearance of the epithelium, pseudo-decidualization in the stroma, and local hemorrhage around the regions of desquamation of epithelium and lysis in the subepithelial stromal tissue, which are characteristics of breakthrough bleeding known to occur with progestational agents. In contrast, no association with the course of genital bleeding was found with respect to changes in serum estradiol, progesterone, follicle stimulating hormone and luteinizing hormone concentrations, plasma dienogest concentration, endometrial thickness or follicular diameter.
INTRODUCTION
D IENOGEST IS A novel 19-nortestosterone derivative synthesized by Bayer Schering Pharma, Berlin, Germany, and supplied by Mochida Pharmaceutical in Japan. Dienogest exhibits highly selective binding to progesterone receptors 1 and exerts antiovulatory 2 and antigonadotrophic 3 activities, as well as antiproliferative activity in isolated human endometrial cells. 4 With this hormonal profile, dienogest would be expected to have a therapeutic effect on endometriosis; and the drug has been investigated in terms of its efficacy and safety in patients with endometriosis in Europe and Japan. 3, 5 In these studies, most of the patients with endometriosis receiving dienogest therapy experienced irregular genital bleeding during the medication period. All 183 cases in a late phase II study in Japan experienced bleeding during 24 weeks of medication with dienogest, 3 although the genital bleeding was considered highly tolerable based on the intensity of spotting or breakthrough bleeding in most cases. No serious cases and a low incidence of discontinuation of the drug as a result of the bleeding were observed. However, the mechanism of genital bleeding with dienogest remains unclear and it is very important to clarify the bleeding mechanism for confirmation of the safety of Japanese patients under dienogest therapy and for dealing with the genital bleeding properly. Unfortunately, no bleeding has been © 2007 The Authors Journal compilation © 2007 Japan Society for Reproductive Medicine reported in the non-clinical studies on dienogest, including those on primates, nor has any experimental animal model to investigate the mechanism of exogenous steroid-induced genital bleeding been established. 6, 7 Because genital bleeding with dienogest was observed in all patients regardless of their background characteristics, 3 in the present study we planned to examine the common mechanism of the genital bleeding using a limited number of subjects through repeated hormonal and histological examinations. Nine patients with symptomatic endometriosis diagnosed by laparotomy, laparoscopy or imaging analysis (combination of magnetic resonance imaging and ultrasonography) of endometriotic ovarian chocolate cysts were enrolled under written informed consent. The mean ± standard deviation (SD) of patient age was 36.6 ± 6.6 years (range 28-49 years); weight was 56.9 ± 8.4 kg (range 39-69 kg); cycle length was 26.7 ± 2.2 days (range 23-30 days); and menstrual duration was 6.7 ± 1.1 days (range 5-8 days). The Beecham classification was stage II in five cases and stage III in four cases. Three patients had a complication of uterine leiomyoma, and three others had adenomyosis. No patient receiving hormonal therapy for endometriosis or with undiagnosed genital bleeding was enrolled in the study to avoid a possible influence on the appearance of genital bleeding by background factors.
MATERIALS AND METHODS
The patients were administered dienogest orally at a dose of 2 mg/day, that is, two intakes of a 1-mg tablet every day starting between the second and fifth days of the menstrual cycle as described in previous studies. 3 The treatment period was set at 16 weeks, and the daily incidence and intensity of genital bleeding were recorded in each patient's diary and were confirmed at every visit by each patient. It has been reported previously 3 that the incidence of genital bleeding peaked by 8 weeks of treatment with dienogest, so scheduled visits were set at once per week until 8 weeks of the treatment period so that we could examine the changes in hormonal and gynecological parameters prior to the first onset of genital bleeding and obtain an endometrial biopsy for histological examination during the first event of genital bleeding. Thereafter, scheduled visits were set at once every 2 weeks between 8 and 16 weeks of treatment so that we could examine the changes in hormonal and gynecological parameters along with the irregularly repeated genital bleeding and obtain a second endometrial biopsy during the bleeding event. To minimize the risk, we limited the endometrial biopsy in each patient to a total of two or less. Laboratory measurements were carried out at every visit to obtain serum concentrations of estradiol by radioimmunoassay (double-antibody method), 8 of progesterone by electrochemiluminescence immunoassay, 9 and of follicle stimulating hormone (FSH) and luteinizing hormone (LH) by chemiluminescence immunoassay. 10 In addition, the plasma concentration of the unchanged form of dienogest was determined using high-performance liquid chromatography; and endometrial thickness and dominant-follicle diameter were measured using ultrasonography. The endometrial specimens from the biopsies were fixed in 10% buffered formalin and the paraffin sections were stained with hematoxylin-eosin (HE) or immunostained for progesterone receptor (PR), estrogen receptor (ER), proliferating cell nuclear antigen (PCNA) to detect cell proliferation, or terminal dUTP nick end labeling (TUNEL) to detect apoptosis for light microscopic observation.
RESULTS
A LL NINE PATIENTS enrolled completed the study.
The duration of treatment with dienogest was 111.8 ± 2.3 days (mean ± SD, range 106-114 days) with more than 90% of scheduled exposure to the drug in all cases, and there was no major deviation from protocol.
Genital bleeding arose in all patients by 8 weeks of the treatment period after the termination of menstruation at the initiation of medication. The course of the duration and intensity of individual genital bleeding along with the treatment period was different in each patient (Fig. 1 ). There was no correlation in the onset, duration or intensity of genital bleeding with all the background data shown above. Genital bleeding disappeared during or after the completion of treatment in all cases, and then the first resumed menstruation was observed at 39.1 ± 19.5 days (mean ± SD, range 22-77 days) after the completion of treatment.
Serum mean concentrations of estradiol, progesterone, FSH and LH at 2-16-weeks of treatment were 19.3-63.3 pg/mL, 0.3 ng/mL, 4.7-9.8 mIU/mL and 2.4-6.7 mIU/ mL, respectively, showing only a small change throughout the treatment period. Plasma mean concentration of the unchanged form of dienogest ranged from 33.7 to 39.4 ng/mL, and was almost constant throughout the
